What Is New about New Antidepressants?
Open accessAbstract
Depressed patients and their physicians naturally expect that each new antidepressant that reaches the market will represent a conceptual and therapeutic advance over previous medications.We can determine how realistic this expectation may be if we review dispassionately the validity of the assumptions that underlie the development of new antidepressants and the data supporting their differential effectiveness. Do Antidepressants Work?
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Dilsaver documented general somatic and gastrointestinal distress; sleep disturbances characterized by initial and middle insomnia or excessively vivid and frightening dreams; akathisia or parkinsonism; hypomania or mania as manifestations of new withdrawal symptoms due to TCA discontinuation.
“In 1980 and 1990s, Dilsaver documented general somatic and gastrointestinal distress; sleep disturbances characterized by initial and middle insomnia or excessively vivid and frightening dreams; akathisia or parkinsonism; hypomania or mania as manifestations of new withdrawal symptoms due to TCA discontinuation [92-95].”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [95]
Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measuredMethodological recommendations for psychological intervention trials suggest reporting the number of patients who deteriorate, which would otherwise be masked by failure-to-improve definitions.
“In the methodological recommendations for trials in psychological interventions [21], it is suggested to indicate in a trial the number of patients who deteriorate, who would otherwise be masked by the definition of failure to improve.”
From The Deceptive Manifestations of Treatment Resistance in Depression: A New Look at the Problem (2020) · cites this paper as [21]
While the interplay among different serotonergic receptors and long-term adaptive mechanisms has been implicated in the emergence of tolerance to SSRIs, no head-to-head comparisons are available for alternative classes, especially for newer generation antidepressant drugs.
“While the interplay among different serotonergic receptors and long-term adaptive mechanisms have been implicated in the emergence of tolerance to SSRIs, no head-to-head comparisons are available for alternative classes, especially for newer generation antidepressant drugs [66, 83].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 84 · Cited by 37
Research works printed but not linked: 7
- [11]11. Zhang F, Shao J, Tian J, Zhong Y, Ye L, Meng X, Liu Q, Wang HR: Antidepressant-like ef- fects of LPM580253, a triple reuptake inhibi- tor. Sci Rep 2016; 6: 24333.
- [27]27. Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, Alkodon M, Yuan P, Pribut HJ, Singh NS, Dossou KS, Fang Y, Huang XB, Mayo CL, Wainer IW, Albuquer- que EX, Thompson SM, Thomas CJ, Zarate CA, Gould TD: NMDAR inhibition-indepen- dent antidepressant actions of ketamine me- tabolites. Nature 2016; 533: 481-486.
- [29]29. Castren E, Kojima M: Brain-derived neuro- trophic factor in mood disorders and antide- pressant treatment. Neurobiol Dis 2017; 97: 119-126.
- [30]30. Newport DJ, Schatzberg AF, Nemeroff CB: Whither ketamine as an antidepressant: pan- acea or toxin? Depress Anxiety 2016; 33: 685- 688.
- [38]38. Saraceni MM, Venci JV, Gandhi MA: Levom- ilnacipran (Fetzima): a new serotonin-nor- epinephrine reuptake inhibitor for the treat- ment of major depressive disorder. J Pharm Pract 2014; 27: 389-395.
- [42]42. Gartiehner G, Hansen RA, Morgan LC, Tha- ler K, Lux L, Van Noord M, Mager U, Thieda P, Gaynes BN, Wilkins T, Strobelberger M, Lloyd S, Reichenpfader U, Lohr KN: Compar- ative benefits and harms of second-genera- tion antidepressants for treating major de- pressive disorder. Ann Intern Med 2011; 155: 772-785.
- [57]57. Singh JB, Fedchin M, Daly E, Xi L, Melman C, De Bruecker G, Tadic A, Sienaert P, Wiegand F, Manji HA, Drevets WC, Van Nueten L: Treatment-resistant depression: a double- bline, double-randomization, placebo-con- trolled study. Biol Psychiatry 2016; 80: 424- 431.
- Authors
- Dubovsky, S. L.
- Affiliations
- University at Buffalo, State University of New York (US)
- Corresponding author
- Dubovsky, Steven L.
- ORCID
- Dubovsky, Steven L.
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2018
- Volume
- 87
- Issue
- 3
- Pages
- 129-139
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W2804693447
- Semantic Scholar
- cc77b81d1452d63c24de5dc5cfdaa7833ad26c6b
- Cited by
- 37
- References
- 84
- Citations by year
- 2024: 4 · 2023: 3 · 2022: 6 · 2021: 5 · 2020: 10 · 2019: 6 · 2018: 3
- FWCI
- 3.87
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- antidepressants, antidepressant drug development, depression, differential effectiveness, clinical trials
- MeSH terms
- Antidepressive Agents, Clinical Trials as Topic, Major Depressive Disorder, Humans, Neurotransmitter Agents, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
